ATE553093T1 - Indazolderivate zur hemmung von trpv1 und verwendungen davon - Google Patents

Indazolderivate zur hemmung von trpv1 und verwendungen davon

Info

Publication number
ATE553093T1
ATE553093T1 AT07814410T AT07814410T ATE553093T1 AT E553093 T1 ATE553093 T1 AT E553093T1 AT 07814410 T AT07814410 T AT 07814410T AT 07814410 T AT07814410 T AT 07814410T AT E553093 T1 ATE553093 T1 AT E553093T1
Authority
AT
Austria
Prior art keywords
indazole derivatives
compounds
inhibiting trpv1
compositions
trpv1
Prior art date
Application number
AT07814410T
Other languages
English (en)
Inventor
Chih-Hung Lee
Brian Brown
Richard Perner
John Darbyshire
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE553093T1 publication Critical patent/ATE553093T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07814410T 2006-08-25 2007-08-24 Indazolderivate zur hemmung von trpv1 und verwendungen davon ATE553093T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84025406P 2006-08-25 2006-08-25
PCT/US2007/076696 WO2008024945A1 (en) 2006-08-25 2007-08-24 Indazole derivatives that inhibit trpv1 and uses thereof

Publications (1)

Publication Number Publication Date
ATE553093T1 true ATE553093T1 (de) 2012-04-15

Family

ID=38739912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07814410T ATE553093T1 (de) 2006-08-25 2007-08-24 Indazolderivate zur hemmung von trpv1 und verwendungen davon

Country Status (9)

Country Link
US (2) US7767705B2 (de)
EP (1) EP2054390B1 (de)
JP (1) JP2010501592A (de)
CN (1) CN101541758A (de)
AT (1) ATE553093T1 (de)
CA (1) CA2661898A1 (de)
MX (1) MX2009002018A (de)
TW (1) TW200824687A (de)
WO (1) WO2008024945A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2661898A1 (en) * 2006-08-25 2008-02-28 Abbott Laboratories Indazole derivatives that inhibit trpv1 and uses thereof
EP2489660A1 (de) * 2008-03-20 2012-08-22 Abbott Laboratories Verfahren zum Herstellen von Mitteln für das zentrale Nervensystem, die TRPV1-Antagonisten sind
US20110262395A1 (en) * 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US8163743B2 (en) * 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
ES2383246T3 (es) 2008-06-05 2012-06-19 Glaxo Group Limited 4-amino-indazoles
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
LT2899191T (lt) 2009-04-30 2017-10-25 Glaxo Group Limited Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai
WO2011067365A1 (en) * 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2012017876A1 (ja) * 2010-08-03 2012-02-09 日本ケミファ株式会社 Ｐ２ｘ４受容体拮抗剤
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US9084786B2 (en) 2010-11-03 2015-07-21 University Of Hawaii Methods and compositions for prevention and treatmentof cardiac hypertrophy
WO2013013816A1 (en) * 2011-07-26 2013-01-31 Grünenthal GmbH Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands
US20160213659A1 (en) 2013-09-24 2016-07-28 George Sylvestre Treatment of burn pain by trpv1 modulators
US10696638B2 (en) * 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
CN117247339B (zh) * 2023-11-16 2024-03-12 潍坊富邦药业有限公司 一种烷基胺衍生物的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043694A (en) 1960-05-23 1962-07-10 Eastman Kodak Co Novel class of 3-indazolinone developing agent
FR1344579A (fr) 1961-11-23 1963-11-29 Sandoz Sa Nouveaux dérivés de l'indole et leur préparation
US3647819A (en) 1969-09-19 1972-03-07 Sterling Drug Inc Indazolylphenylureas and indazolyl-phenylthioureas
US3711610A (en) 1971-06-01 1973-01-16 Sterling Drug Inc Anticoccidiosis method and compositions involving indazolylphenylureas and indazolylphenylthioureas
US3814711A (en) 1971-07-26 1974-06-04 Mallinckrodt Chemical Works 10-acetamido-s-triazolo-(3,4-a)-isoquinolines
NL7902993A (nl) 1978-04-24 1979-10-26 Rhone Poulenc Ind Nieuwe isochinolinederivaten, de bereiding ervan en farmaceutische preparaten, die de nieuwe isochinoline- derivaten bevatten.
JPS5587771A (en) 1978-12-27 1980-07-02 Teikoku Hormone Mfg Co Ltd 1-phenylisoquinoline derivative
DE3430310A1 (de) 1984-08-15 1986-02-27 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue dopamin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO1986001204A1 (en) 1984-08-15 1986-02-27 Schering Aktiengesellschaft New dopamine derivatives, process for their production, and their use as medicinal products
US4569779A (en) 1985-01-03 1986-02-11 Jabalee Walter J Solution for cleansing a cooling system
JPS62116559A (ja) 1985-11-18 1987-05-28 Sagami Chem Res Center ４−アシルメチリデン−４，５，６，７−テトラヒドロインド−ル誘導体及びその製造方法
US4788206A (en) 1987-07-10 1988-11-29 Hoffmann-La Roche Inc. Pentadieneamides
JPS6487629A (en) 1987-09-28 1989-03-31 Mitsubishi Petrochemical Co Production of aromatic poly(thio)ether amide
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
JPH05504968A (ja) 1990-03-07 1993-07-29 ローン―プーラン・ロレ・ソシエテ・アノニム グリシンアミド誘導体、その製造及びそれを含む医薬品
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
US5444038A (en) 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
AU4028393A (en) 1992-05-28 1993-12-30 Pfizer Inc. New (N)-aryl and (N)-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (ACAT)
US5374643A (en) 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
GB9307833D0 (en) 1993-04-15 1993-06-02 Glaxo Inc Modulators of cholecystokinin and gastrin
NZ330216A (en) 1996-01-16 2000-09-29 Bristol Myers Squibb Co Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and use in treatment of atherosclerosis
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US6140368A (en) 1997-05-05 2000-10-31 The Regents Of The University Of California Naphthols useful in antiviral methods
WO2000050387A1 (en) 1999-02-22 2000-08-31 Pacific Corporation Vanilloid analogues containing resiniferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof
AU778393B2 (en) 1999-05-12 2004-12-02 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
JP2001122895A (ja) 1999-10-20 2001-05-08 Hamari Chemicals Ltd 新規なオピオイドペプチド誘導体
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
EP1262475A4 (de) 2000-03-09 2005-01-05 Ono Pharmaceutical Co Indolderivate, verfahren zu ihrer herstellung und deren verwendung
EP1301484A2 (de) 2000-07-20 2003-04-16 Neurogen Corporation Capsaicin-rezeptor-liganden
TWI239942B (en) 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
WO2003014064A1 (en) 2001-07-31 2003-02-20 Bayer Healthcare Ag Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
MY138086A (en) 2001-09-13 2009-04-30 Smithkline Beecham Plc Novel urea derivative as vanilloid receptor-1 antagonist
US20040259912A1 (en) 2001-09-28 2004-12-23 Takahiro Matsumoto Benzine derivatives, process for preparing the same and use thereof
JP2005518371A (ja) 2001-12-10 2005-06-23 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療に於けるこれらの使用
GB0130550D0 (en) 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel compounds
JP2003192587A (ja) 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
WO2003055848A2 (en) 2001-12-26 2003-07-10 Bayer Healthcare Ag Urea derivatives as vr1- antagonists
CA2476936A1 (en) 2002-02-20 2003-08-28 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
WO2003097586A1 (en) 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
US6933311B2 (en) 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
JP2005036929A (ja) * 2003-07-17 2005-02-10 Advics:Kk 電磁弁の弁軸付可動鉄心及びその製造方法
GB0322016D0 (en) * 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
CA2661898A1 (en) * 2006-08-25 2008-02-28 Abbott Laboratories Indazole derivatives that inhibit trpv1 and uses thereof

Also Published As

Publication number Publication date
TW200824687A (en) 2008-06-16
CN101541758A (zh) 2009-09-23
EP2054390B1 (de) 2012-04-11
US7767705B2 (en) 2010-08-03
US20080058401A1 (en) 2008-03-06
EP2054390A1 (de) 2009-05-06
US20100249203A1 (en) 2010-09-30
CA2661898A1 (en) 2008-02-28
MX2009002018A (es) 2009-03-05
US8815930B2 (en) 2014-08-26
WO2008024945A1 (en) 2008-02-28
JP2010501592A (ja) 2010-01-21

Similar Documents

Publication Publication Date Title
ATE553093T1 (de) Indazolderivate zur hemmung von trpv1 und verwendungen davon
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
SI2134691T1 (sl) Derivati kvinolina kot PARP in TANK inhibitorji
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
NO20091326L (no) Indazolderivater som modulatorer av interleukin-1-reseptor-assosiert kinase
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
EA201070238A1 (ru) Соединения пиримидина
MX2010007392A (es) Antagonistas de trpa1.
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
MX2010007391A (es) Antagonistas de trpa1.
ATE544761T1 (de) Pyrimidinderivate und zusammensetzungen als c-kit-und pdgfr-kinasehemmer
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
MX2009006730A (es) Derivados de n-(5, 6, 7, 8-tetrahidronaftalen-1-il) urea y compuestos relacionados como antagonistas de receptor vaniloide trpv1 par el tratamiento de dolor.
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
MX2010004498A (es) Derivados de ciclohexenoamida y su uso como antagonistas de trpv1.
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
NO20091052L (no) Diaryleterderivater og anvendelser derav
MX2011007165A (es) Derivados de piridazinona.
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
MX2008001538A (es) Aril piridinas y metodos para su uso.
MX2010004495A (es) Derivados de 2-aminooxazol como antagonistas de vanilloide-1 de receptor potencial transitorio (trpv1) utiles para tratar dolor.